Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 12/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | YEATS4 | O95619 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8276754 | 0.90 | HTR4 (0.35) | HTR4NCF1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL8276763 | 0.90 | HTR4 (0.35) | HTR4NCF1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2966813 | 0.81 | HTR4 (0.42) | HTR4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3337075 | 0.80 | NCF1 (0.41) | HTR4NCF1CXCR4 | |
| SCHEMBL3337071 | 0.80 | NCF1 (0.41) | HTR4NCF1CXCR4 | |
| SCHEMBL3337067 | 0.80 | NCF1 (0.41) | HTR4NCF1CXCR4 | |
| SCHEMBL5600775 | 0.80 | NCF1 (0.41) | HTR4NCF1CXCR4 | |
| SCHEMBL1970098 | 0.78 | PLG (0.35) | HTR4NCF1ALDH1A1CXCR4 | |
| SCHEMBL2974078 | 0.78 | SMN1; SMN2 (0.49) | HTR4SMN1; SMN2POLBYEATS4KCNH2 | |
| SCHEMBL3164794 | 0.76 | HTR4 (0.53) | HTR4POLBYEATS4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362038-B2 | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity | PFIZER INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-1664036-B1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2011-12-28 | — | — | EP | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | PFIZER INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-1689742-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1664036-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005092882-A1 | 4-AMINO-5-HALOGENO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, CNS, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005073222-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
| WO-2005073222-A1 | 1-ISOPROPYL-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-08-11 | — | — | WO | disclosed |
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | PFIZER INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021539-A1 | BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148573-A1 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity | HTR4, GPR4, HTR5A | HTR4 1/4885NCF1 2503/4885ALDH1A1 2462/4885 |
| US-20100273794-A1 | Benzimidazolone Compounds Having 5-HT4 Receptor Agonistic Activity | HTR4, GPR4, HTR5A | HTR4 1/4885NCF1 2503/4885ALDH1A1 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.